Financials data is unavailable for this security.
View more
Year on year EZZ Life Science Holdings Ltd grew revenues 78.88% from 37.14m to 66.44m while net income improved 91.87% from 3.63m to 6.96m.
Gross margin | 76.67% |
---|---|
Net profit margin | 10.48% |
Operating margin | 17.98% |
Return on assets | 32.25% |
---|---|
Return on equity | 38.79% |
Return on investment | 38.61% |
More ▼
Cash flow in AUDView more
In 2024, EZZ Life Science Holdings Ltd increased its cash reserves by 37.54%, or 5.19m. The company earned 6.14m from its operations for a Cash Flow Margin of 9.25%. In addition the company used 441.17k on investing activities and also paid 582.45k in financing cash flows.
Cash flow per share | 0.1707 |
---|---|
Price/Cash flow per share | 18.84 |
Book value per share | 0.4801 |
---|---|
Tangible book value per share | 0.4797 |
More ▼
Balance sheet in AUDView more
Current ratio | 5.96 |
---|---|
Quick ratio | 5.63 |
Total debt/total equity | 0.0058 |
---|---|
Total debt/total capital | 0.0058 |
More ▼
Growth rates in AUD
Year on year, growth in earnings per share excluding extraordinary items increased 90.18%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
Div yield(5 year avg) | 0.99% |
---|---|
Div growth rate (5 year) | -- |
Payout ratio (TTM) | 9.20% |
EPS growth(5 years) | 52.48 |
---|---|
EPS (TTM) vs TTM 1 year ago | 89.00 |
More ▼